Mogrify Ltd, a UK company aiming to transform the future development of cell therapies, today announced that it has moved to the Bio-Innovation Centre at the Cambridge Science Park, following the appointment of 15 new staff to its scientific and management teams.
Mogrify strengthens team and relocates to the Bio-Innovation Centre, TusPark Cambridge
Appointments include Dr Karin Schmitt as Chief Business Officer and Joe Foster as Chief Operating Officer. These new hires and facilities will aid Mogrify in building a scalable infrastructure to generate IP around novel cell conversion to power the development and manufacture of new cell therapies across multiple therapeutic areas.
Mogrify is located at TusPark’s Cambridge Bio-Innovation Centre featuring facilities for biotech research and health-tech innovation. The Bio-Innovation Centre is the first of its kind to be built at the Cambridge Science Park and is fitted with laboratories for multiple occupiers in the life sciences sector. Mogrify is its anchor tenant and occupies 12,000 sq. ft of laboratory and office space.
The new team members include cell scientists, bioinformaticians and executives, bringing the Company’s headcount currently to 20.
Dr Karin Schmitt will lead Mogrify’s commercial operations and its R&D function in her role as Chief Business Officer. She has over 25 years’ experience with a sustained track record of successful leadership roles within the life sciences, biotech and therapeutic industries at Exelixis, Inc., Millennium Pharmaceuticals, Thermo Fisher Scientific, Horizon Discovery Group plc and PredictImmune Ltd. Karin has brought over 20 innovative products to market internationally, across a wide scientific spectrum, with recent emphasis on clinical products and has additional experience in legal, commercial and regulatory pathways. Karin obtained her PhD in Molecular Biology at the University of Southern California in Los Angeles, followed by three years of post-doctoral research in genetics at the University of Cambridge.
Joe Foster’s role as Chief Operating Officer will consist of managing the corporate operations as well as driving Mogrify’s IP management function. He began his career at Horizon Discovery Group plc working within the corporate development team gaining experience in business planning, licensing, technology evaluation and M&A analysis, before becoming Dr. Jonathan Milner's (Co-founder of Abcam plc) Portfolio Manager where he built and managed a complex portfolio of more than 40 early-stage life science companies. Joe holds a degree in Molecular & Cellular Biology from the University of Bath and an MPhil in Business Management from the University of Cambridge.
Dr. Darrin M. Disley, OBE, CEO, Mogrify, said: “We are growing a world-class scientific and executive team that will enable Mogrify to become a global leader in the development of novel cell conversion IP that underpins the development of lifesaving cell therapies. The new Bio-Innovation Centre at the Cambridge Science Park offers outstanding facilities, service and networks to its tenants and we’re thrilled to be joining them at this exciting time.”
Kevin Lin, President, TusPark UK, said: “Mogrify’s direct cellular conversion technology has the potential to transform cell therapy and we’re delighted to have their expert team join us at our new state-of-the-art research facilities at the center of the Cambridge cluster.”
For further information about Mogrify’s team, please visit: https://mogrify.co.uk/our-people/
Image: Mogrify leadership team Credit Phil Mynott